SARS-CoV-2 and Systemic Lupus Erythematosus

[1] Kaul A(2016)Systemic lupus erythematosus Na Rev Dis Primers 2 16039-1294

[2] Gordon C(2020)COVID-19: immunology and treatment options Clin Immunol 215 108448-941

[3] Crow MK(2013)Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies Lupus. 22 1286-ee5

[4] Touma Z(2020)Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study BMJ. 369 m1966-206

[5] Urowitz MB(2020)Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study BMJ. 369 m1985-1063

[6] van Vollenhoven R(2020)Immunology of COVID-19: current state of the science Immunity. 52 910-474

[7] Ruiz-Irastorza G(2020)The renin-angiotensin system - a therapeutic target in COVID-19? Clin Med (Lond) 20 e72-115

[8] Hughes G(2020)COVID-19 diagnosis and management: a comprehensive review J Intern Med 288 192-589

[9] Felsenstein S(2020)Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions Autoimmun Rev 19 102567-290

[10] Herbert JA(2020)The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic Mult Scler Relat Disord 43 102174-2201

[1] Kaul A(2016)Systemic lupus erythematosus Na Rev Dis Primers 2 16039-1294

[2] Gordon C(2020)COVID-19: immunology and treatment options Clin Immunol 215 108448-941

[3] Crow MK(2013)Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies Lupus. 22 1286-ee5

[4] Touma Z(2020)Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study BMJ. 369 m1966-206

[5] Urowitz MB(2020)Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study BMJ. 369 m1985-1063

[6] van Vollenhoven R(2020)Immunology of COVID-19: current state of the science Immunity. 52 910-474

[7] Ruiz-Irastorza G(2020)The renin-angiotensin system - a therapeutic target in COVID-19? Clin Med (Lond) 20 e72-115

[8] Hughes G(2020)COVID-19 diagnosis and management: a comprehensive review J Intern Med 288 192-589

[9] Felsenstein S(2020)Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions Autoimmun Rev 19 102567-290

[10] Herbert JA(2020)The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic Mult Scler Relat Disord 43 102174-2201